检索规则说明:AND代表“并且”;OR代表“或者”;NOT代表“不包含”;(注意必须大写,运算符两边需空一格)
检 索 范 例 :范例一: (K=图书馆学 OR K=情报学) AND A=范并思 范例二:J=计算机应用与软件 AND (U=C++ OR U=Basic) NOT M=Visual
机构地区:[1]中山大学附属第三医院不育与性医学科,广东广州510630
出 处:《临床医学工程》2008年第9期25-26,共2页Clinical Medicine & Engineering
摘 要:目的:观察耻骨后药物注射结合局部理疗治疗慢性前列腺炎的疗效。方法:回顾性总结根据美国国立卫生研究院(NIH)标准诊断为Ⅱ型及Ⅲ型经口服药物治疗效果欠佳的慢性前列腺炎患者197例,年龄17~61岁,美国国立卫生研究院慢性前列腺炎症状评分(NIH-CPSI)>19分,用庆大霉素8万U、1%利多卡因2ml注射至耻骨后间隙前列腺外周,每2~3天1次,共6~9次,注射后次日开始40℃~42℃热水坐浴15~20min,每日2次,也可经直肠射频或微波治疗,隔日1次。治疗期间禁烟酒及辛辣饮食,忌久坐、少骑车。采用NIH-CPSI评分的改变判定疗效。结果:观察4~8周,治愈69例(35%),显效92例(47%),有效19例(10%),无效17例(9%),总有效率91%。1例出现排尿轻微疼痛,持续1d,未经治疗而自行消失。结论:耻骨后前列腺穿刺注射结合局部理疗治疗慢性前列腺炎方便、安全、有效。Objective To observe the curative effects on the treatment of 197 cases of chronic prostatitis by combination of retropubic pharmaceutics injection and local physicotherapeutics. Methods 197 patients of our department diagnosed as type Ⅱ and type Ⅲ chronic prostatitis according to NIH standardization were retrospectively studied between September 2006 and May 2008.All these patients had poor improvement with oral medication.Their age ranged from 17to 61 years old and their scores evaluated by NIH-CPSI(NIH classification system for prostatitis) were higher than 19.Eighty thousand units of gentamycin and 2ml of lidocaine with one percent concentration were injected together to the periphery ofprostatae 2 to 3 times a day,6 to 9 times in total. The curative effect was evaluated by using the changes of NIH-CPSI. Results After 4 to 8 week' s observation, 69 cases were cured(35%),92 cases had an evidently effect(47%),19 cases had a helpful effect(10%), 17 cases had no effect(9%).The total efficiency was 91%.2 cases had a little pain during urination and the symptom disappeared after one day without any treatment. Conclusion Combination of retropubic pharmaceutics injection and local physicotherapeutics is a convenient, safe and effective treatment on patients with chronic prostatitis.
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在链接到云南高校图书馆文献保障联盟下载...
云南高校图书馆联盟文献共享服务平台 版权所有©
您的IP:216.73.216.117